BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Duvoglustat: Phase II started

Amicus began an open-label, international Phase II trial comparing 4 single ascending-doses of oral AT2220 plus alglucosidase alfa vs. alglucosidase alfa alone in about 16 patients. In 2009, FDA placed a clinical hold on AT2220 and Amicus suspended enrollment in...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >